Omnicell, Inc. (NASDAQ:OMCL) Shares Sold by Geneva Capital Management LLC

Geneva Capital Management LLC reduced its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 34.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 619,254 shares of the company’s stock after selling 319,690 shares during the quarter. Geneva Capital Management LLC owned about 1.35% of Omnicell worth $18,101,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of OMCL. Neo Ivy Capital Management acquired a new stake in shares of Omnicell in the 3rd quarter valued at approximately $78,000. Benjamin Edwards Inc. increased its stake in Omnicell by 36.4% in the 1st quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock valued at $95,000 after purchasing an additional 868 shares in the last quarter. Strs Ohio increased its stake in Omnicell by 28.2% in the 4th quarter. Strs Ohio now owns 5,000 shares of the company’s stock valued at $188,000 after purchasing an additional 1,100 shares in the last quarter. Hsbc Holdings PLC purchased a new position in Omnicell in the 3rd quarter valued at approximately $200,000. Finally, Aristides Capital LLC purchased a new position in Omnicell in the 4th quarter valued at approximately $269,000. 97.70% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

OMCL has been the subject of several research analyst reports. Benchmark reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Omnicell in a research note on Tuesday, April 30th. StockNews.com raised Omnicell from a “hold” rating to a “buy” rating in a research note on Monday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, Omnicell currently has an average rating of “Hold” and a consensus target price of $42.20.

Omnicell Price Performance

Omnicell stock traded up $1.16 during mid-day trading on Thursday, hitting $26.77. 405,532 shares of the company were exchanged, compared to its average volume of 520,490. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.38 and a quick ratio of 2.13. The business’s 50 day simple moving average is $29.25 and its two-hundred day simple moving average is $29.84. The company has a market capitalization of $1.23 billion, a P/E ratio of -57.61, a PEG ratio of 93.23 and a beta of 0.80. Omnicell, Inc. has a 12-month low of $25.12 and a 12-month high of $75.07.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.17. The company had revenue of $246.15 million during the quarter, compared to the consensus estimate of $235.70 million. Omnicell had a positive return on equity of 2.41% and a negative net margin of 1.91%. Analysts forecast that Omnicell, Inc. will post 0.2 earnings per share for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.